37 related articles for article (PubMed ID: 31648166)
1. Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma.
Afaq F; Agarwal S; Bajpai P; Diffalha SA; Kim HG; Peter S; Khushman M; Chauhan SC; Mukherjee P; Varambally S; Manne U
Neoplasia; 2024 Jan; 47():100951. PubMed ID: 38039923
[TBL] [Abstract][Full Text] [Related]
2. ID3 is a novel target gene of p53 and modulates lung cancer cell metastasis.
Nagasaka M; Miyajima C; Inoue Y; Hashiguchi S; Suzuki Y; Morishita D; Aoki H; Toriuchi K; Katayama R; Aoyama M; Hayashi H
Biochem Biophys Res Commun; 2024 May; 708():149789. PubMed ID: 38513475
[TBL] [Abstract][Full Text] [Related]
3. Targeting tumor suppressor p53 for organ fibrosis therapy.
Bao YN; Yang Q; Shen XL; Yu WK; Zhou L; Zhu QR; Shan QY; Wang ZC; Cao G
Cell Death Dis; 2024 May; 15(5):336. PubMed ID: 38744865
[TBL] [Abstract][Full Text] [Related]
4. RIOK1 synergizes with TRIP13 by regulating the E2F-Rb signaling pathway to promote the proliferation of esophageal cancer cells.
Li C; Pan D; Lin W; Deng D; Zhou Y; Zhao H; Pan F; Xu L; Li E; Long L
Genes Dis; 2024 May; 11(3):100990. PubMed ID: 38274384
[No Abstract] [Full Text] [Related]
5. TRIP13 promotes the cell proliferation, migration and invasion of glioblastoma through the FBXW7/c-MYC axis.
Zhang G; Zhu Q; Fu G; Hou J; Hu X; Cao J; Peng W; Wang X; Chen F; Cui H
Br J Cancer; 2019 Dec; 121(12):1069-1078. PubMed ID: 31740732
[TBL] [Abstract][Full Text] [Related]
6. TRIP13 regulates DNA repair pathway choice through REV7 conformational change.
Clairmont CS; Sarangi P; Ponnienselvan K; Galli LD; Csete I; Moreau L; Adelmant G; Chowdhury D; Marto JA; D'Andrea AD
Nat Cell Biol; 2020 Jan; 22(1):87-96. PubMed ID: 31915374
[TBL] [Abstract][Full Text] [Related]
7. TRIP13 predicts poor prognosis in clear cell renal cell carcinoma.
Kowalewski A; Jaworski D; Antosik P; Smolińska M; Ligmanowska J; Grzanka D; Szylberg Ł
Am J Cancer Res; 2020; 10(9):2909-2918. PubMed ID: 33042625
[TBL] [Abstract][Full Text] [Related]
8. TRIP13 promotes metastasis of colorectal cancer regardless of p53 and microsatellite instability status.
Agarwal S; Behring M; Kim HG; Chandrashekar DS; Chakravarthi BVSK; Gupta N; Bajpai P; Elkholy A; Al Diffalha S; Datta PK; Heslin MJ; Varambally S; Manne U
Mol Oncol; 2020 Dec; 14(12):3007-3029. PubMed ID: 33037736
[TBL] [Abstract][Full Text] [Related]
9. The oncogenic role of TRIP13 in regulating proliferation, invasion, and cell cycle checkpoint in NSCLC cells.
Zhang Q; Dong Y; Hao S; Tong Y; Luo Q; Aerxiding P
Int J Clin Exp Pathol; 2019; 12(9):3357-3366. PubMed ID: 31934178
[TBL] [Abstract][Full Text] [Related]
10. TRIP13 promotes lung cancer cell growth and metastasis through AKT/mTORC1/c-Myc signaling.
Cai W; Ni W; Jin Y; Li Y
Cancer Biomark; 2021; 30(2):237-248. PubMed ID: 33136091
[TBL] [Abstract][Full Text] [Related]
11. TRIP13 promotes the proliferation and invasion of lung cancer cells via the Wnt signaling pathway and epithelial-mesenchymal transition.
Li ZH; Lei L; Fei LR; Huang WJ; Zheng YW; Yang MQ; Wang Z; Liu CC; Xu HT
J Mol Histol; 2021 Feb; 52(1):11-20. PubMed ID: 33128167
[TBL] [Abstract][Full Text] [Related]
12. TTC5 mediates autoregulation of tubulin via mRNA degradation.
Lin Z; Gasic I; Chandrasekaran V; Peters N; Shao S; Mitchison TJ; Hegde RS
Science; 2020 Jan; 367(6473):100-104. PubMed ID: 31727855
[TBL] [Abstract][Full Text] [Related]
13. A Small-Molecule Inhibitor Targeting TRIP13 Suppresses Multiple Myeloma Progression.
Wang Y; Huang J; Li B; Xue H; Tricot G; Hu L; Xu Z; Sun X; Chang S; Gao L; Tao Y; Xu H; Xie Y; Xiao W; Yu D; Kong Y; Chen G; Sun X; Lian F; Zhang N; Wu X; Mao Z; Zhan F; Zhu W; Shi J
Cancer Res; 2020 Feb; 80(3):536-548. PubMed ID: 31732653
[TBL] [Abstract][Full Text] [Related]
14. TRIP13 overexpression promotes gefitinib resistance in non‑small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathway.
Xiao Z; Li M; Zhang X; Rong X; Xu H
Oncol Rep; 2023 May; 49(5):. PubMed ID: 36896765
[TBL] [Abstract][Full Text] [Related]
15. Ultrasound-targeted microbubble destruction (UTMD)-mediated miR-150-5p attenuates oxygen and glucose deprivation-induced cardiomyocyte injury by inhibiting TTC5 expression.
Zhong X; Chen Y; Long X; Chen H; Zheng Z; Pan H; Peng J; Liu Y; Wang H; Hu Y
Mol Biol Rep; 2022 Jul; 49(7):6041-6052. PubMed ID: 35357625
[TBL] [Abstract][Full Text] [Related]
16. CD105 expression is associated with invasive capacity in ovarian cancer and promotes invasiveness by inhibiting NDRG1 and regulating the epithelial-mesenchymal transition.
Zhang J; Sang X; Zhang R; Chi J; Bai W
Am J Transl Res; 2021; 13(11):12461-12479. PubMed ID: 34956466
[TBL] [Abstract][Full Text] [Related]
17. TRIP13 interference inhibits the proliferation and metastasis of thyroid cancer cells through regulating TTC5/p53 pathway and epithelial-mesenchymal transition related genes expression.
Yu L; Xiao Y; Zhou X; Wang J; Chen S; Peng T; Zhu X
Biomed Pharmacother; 2019 Dec; 120():109508. PubMed ID: 31648166
[TBL] [Abstract][Full Text] [Related]
18. Thyroid Receptor-Interacting Protein 13 is Correlated with Progression and Poor Prognosis in Bladder Cancer.
Niu L; Gao Z; Cui Y; Yang X; Li H
Med Sci Monit; 2019 Sep; 25():6660-6668. PubMed ID: 31486418
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
